Who is the CEO of RayzeBio, Inc. Common Stock?

The CEO of RayzeBio, Inc. Common Stock is Kenneth Song.

What industry does RayzeBio, Inc. Common Stock belong to?

RayzeBio, Inc. Common Stock operates in the Biotechnology industry within the Healthcare sector.

Where is RayzeBio, Inc. Common Stock headquartered?

RayzeBio, Inc. Common Stock is headquartered at DE, US.

What is the IPO date of RayzeBio, Inc. Common Stock?

RayzeBio, Inc. Common Stock went public on September 15, 2023.

How many employees does RayzeBio, Inc. Common Stock have?

RayzeBio, Inc. Common Stock has approximately 88 full-time employees.

RayzeBio, Inc. Common Stock

RYZB•NASDAQ

Healthcare

Biotechnology

$62.49

$0.01(0.02%)

RayzeBio, Inc. Common Stock (RYZB) Company Profile & Overview

Explore RayzeBio, Inc. Common Stock’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

RayzeBio, Inc. Common Stock (RYZB) Company Profile & Overview

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.

SectorHealthcare

IndustryBiotechnology

CEOKenneth Song

Contact Information

Company Facts

88 Employees

IPO DateSep 15, 2023

CountryUS

Frequently Asked Questions

;